

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1579-628

C# M#

HALE et al

Group Art Unit:


Serial No. 09/998,923

Examiner:

Filed: December 3, 2001

Date: August 14, 2002

Title: ZINC ALPHA-2-GLYCOPROTEIN AS INDICATOR OF CANCER

Assistant Commissioner for Patents
Washington, DC 20231IDS/#5
8.16.02
RECEIVED
AUG 15 2002
TECH CENTER 1600/2900

Sir:

INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment **e** minus highest number
previously paid for **20** (at least 20) = **0** x \$ 18.00 \$ 0.00

Independent claims after amendment **0** minus highest number
previously paid for **3** (at least 3) = **0** x \$ 84.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) \$ 0.00

☐ Please enter the previously unentered , filed

☐ Submission attached

Subtotal \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: 0.00

TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
MJW:tat

NIXON & VANDERHYE P.C.
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

HALE et al

Atty. Ref.: 1579-628

Serial No.: 09/998,923

Group Art Unit:

Filed: December 3, 2001

Examiner:

For: ZINC ALPHA-2-GLYCOPROTEIN AS INDICATOR OF CANCER

* * * * *

August 14, 2002

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents
and Trademarks
Washington, DC 20231

Sir:

RECEIVED

AUG 15 2002

TECH CENTER 1600/2900

Each enclosed document listed on the herewith Form PTO-1449 was cited in the attached International Search Report, dated August 2, 2002, issued in a counterpart International application not more than three months ago.

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith Form PTO-1449 with the



HALE et al -- Serial No.: 09/998,923

Examiner's initials in the left column per MPEP 609 are
earnestly solicited.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

By Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

MJW:tat

1100 North Glebe Road
8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

SERIAL NO.

1579-628

09/998,923

APPLICANT

HALE et al

(Use several sheets if necessary)

FILING DATE

GROUP

December 3, 2001

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	<p>Todorov et al, "Purification and Characterization of a Tumor Lipid-mobilizing Factor", Cancer Research 58:2353-2358 (1998)</p>		
	<p>Bundred et al, "Zinc Alpha-2 Glycoprotein Levels in Serum and Breast Fluids: a Potential Marker of Apocrine Activity", Eur. J. Cancer 27(5):549-552 (1991)</p>		
	<p>Hale et al, "Zinc α-2-Glycoprotein Is Expressed by Malignant Prostatic Epithelium and May Serve as a Potential Serum Marker for Prostate Cancer", Clinical Cancer Research 7:846-853 (2001)</p>		
	<p>Lopez-Otin and Diamandis, "Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical Features", Endocrine Reviews 19(4):365-396 (1998)</p>		
*Examiner		Date Considered	

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)